Automated summaries of serious adverse events in the hepatitis C antiviral long-term treatment against cirrhosis trial

被引:2
|
作者
Bell, Margaret C. [1 ]
Robuck, Patricia R. [2 ]
Wright, Elizabeth C. [3 ]
Mihova, Marina S. [1 ]
Hofmann, Charlotte [4 ]
De Santo, Jennifer L. [5 ]
Milstein, Susan L. [6 ]
Richtmyer, Pamela A. [1 ,7 ]
Shelton, Janel L. [8 ]
Cormier, Maureen [9 ]
King, Debra L. [10 ]
Park, Choon J. [11 ]
Molchen, Wallis A. [12 ]
Park, Yoon [13 ]
Kelley, Michelle [14 ]
机构
[1] New England Res Inst, Watertown, MA 02472 USA
[2] NIDDKD, Div Digest Dis & Nutr, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA
[3] NIDDKD, Off Director, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA
[4] Virginia Commonwealth Univ, Med Ctr, Hepatol Sect, Richmond, VA USA
[5] Univ Colorado Denver, Div Gastroenterol & Hepatol, Aurora, CO USA
[6] Univ So Calif, Hepatitis Res & Treatment Ctr, Los Angeles, CA USA
[7] Univ Michigan, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI 48109 USA
[8] Univ Texas SW Med Ctr Dallas, Div Digest & Liver Dis, Dallas, TX 75390 USA
[9] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA
[10] St Louis Univ, Sch Med, Div Gastroenterol & Hepatol, St Louis, MO USA
[11] Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA
[12] Massachusetts Gen Hosp, Gastrointestinal Unit, Med Serv, Boston, MA 02114 USA
[13] NIDDKD, Liver Dis Branch, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA
[14] Univ Connecticut Hlth Care, Gen Clin Res Ctr, Farmington, CT USA
基金
美国国家卫生研究院;
关键词
EVOLUTION;
D O I
10.1177/1740774509348525
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background Even though adverse event (AE) collection and official accounting are mandatory for clinical trials, there are limited detailed guidelines specifying how to summarize the event for reporting in a timely and expeditious manner. This article details the AE and serious adverse event (SAE) reporting summary developed for a large multi-center National Institutes of Health (NIH)-sponsored clinical trial. Purpose To review and analyze the large volume of AE data reported by 10 sites (806 SAEs and 19,034 AEs from August 2000 to May 2007) the automated SAE summary was developed. It was designed to ensure timeliness and clarity in the complex process of AE review and reporting. Methods The AE and SAE case report forms (CRFs) as well as the automated SAE summary were developed within a database management system developed by the Data Coordinating Center (DCC) which allowed for web-based data entry at the DCC and 10 sites and offered immediate overall and site-specific reports accessible by the DCC, site, and NIH project staff. Results The automated SAE summary pulled data from multiple CRFs to create a succinct and informative summary and allowed for prompt and easy reporting to the regulatory agencies. The summary was adaptable to the needs of reviewers because of the availability of multiple search options.
引用
收藏
页码:618 / 627
页数:10
相关论文
共 50 条
  • [1] Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial
    Freedman, N. D.
    Curto, T. M.
    Morishima, C.
    Seeff, L. B.
    Goodman, Z. D.
    Wright, E. C.
    Sinha, R.
    Everhart, J. E.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (01) : 127 - 137
  • [2] Hepatic steatosis in hepatitis C: Comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial
    Lok, Anna S. F.
    Everhart, James E.
    Chung, Raymond T.
    Padmanabhan, Latha
    Greenson, Joel K.
    Shiffman, Mitchell L.
    Everson, Gregory T.
    Lindsay, Karen L.
    Bonkovsky, Herbert L.
    Di Bisceglie, Adrian M.
    Lee, William M.
    Morgan, Timothy R.
    Ghany, Marc G.
    Morishima, Chihiro
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2007, 5 (02) : 245 - 254
  • [3] Clinical model to predict cirrhosis in patients in the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.
    Lok, AS
    Everhart, JE
    Everson, G
    Wright, EC
    Sterling, R
    Ghany, M
    Goodman, Z
    HEPATOLOGY, 2002, 36 (04) : 315A - 315A
  • [4] Design of the halt-c trial (hepatitis C antiviral long-term treatment to prevent cirrhosis).
    Di Bisceglie, AM
    Bonkovsky, HL
    Dienstag, JL
    Everson, GT
    Lindsay, KL
    Gretch, DR
    Hoefs, JC
    Lee, WH
    Lok, AS
    Tralka, TS
    Shiffman, ML
    Wright, EC
    GASTROENTEROLOGY, 2000, 118 (04) : A1435 - A1435
  • [5] Weight-Related Effects on Disease Progression in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial
    Everhart, James E.
    Lok, Anna S.
    Kim, Hae-Young
    Morgan, Timothy R.
    Lindsay, Karen L.
    Chung, Raymond T.
    Bonkovsky, Herbert L.
    Ghany, Marc G.
    GASTROENTEROLOGY, 2009, 137 (02) : 549 - 557
  • [6] Herbal product use by persons enrolled in the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial
    Seeff, Leonard B.
    Curto, Teresa M.
    Szabo, Gyongyi
    Everson, Gregory T.
    Bonkovsky, Herbert L.
    Dienstag, Jules L.
    Shifftnan, Mitchell L.
    Lindsay, Karen L.
    Lok, Anna S. F.
    Di Bisceglie, Adrian M.
    Lee, William M.
    Ghany, Marc G.
    HEPATOLOGY, 2008, 47 (02) : 605 - 612
  • [7] HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial
    Morishima, Chihiro
    Morgan, Timothy R.
    Everhart, James E.
    Wright, Elizabeth C.
    Shiffman, Mitchell L.
    Everson, Gregory T.
    Lindsay, Karen L.
    Lok, Anna S. F.
    Bonkovsky, Herbert L.
    Di Bisceglie, Adrian M.
    Lee, William M.
    Dienstag, Jules L.
    Ghany, Marc G.
    Gretch, David R.
    HEPATOLOGY, 2006, 44 (02) : 360 - 367
  • [8] Prognostic Value of Ishak Fibrosis Stage: Findings from the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial
    Everhart, James E.
    Wright, Elizabeth C.
    Goodman, Zachary D.
    Dienstag, Jules L.
    Hoefs, John C.
    Kleiner, David E.
    Ghany, Marc G.
    Mills, A. Scott
    Nash, S. Russell
    Govindarajan, Sugantha
    Rogers, Thomas E.
    Greenson, Joel K.
    Brunt, Elizabeth M.
    Bonkovsky, Herbert L.
    Morishima, Chihiro
    Litman, Heather J.
    HEPATOLOGY, 2010, 51 (02) : 585 - 594
  • [9] Evolution of Hepatic Steatosis in Patients with Advanced Hepatitis C: Results from the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial
    Lok, Anna S.
    Everhart, James E.
    Chung, Raymond T.
    Kim, Hae-Young
    Everson, Gregory T.
    Hoefs, John C.
    Greenson, Joel K.
    Sterling, Richard K.
    Lindsay, Karen L.
    Lee, William M.
    Di Bisceglie, Adrian M.
    Bonkovsky, Herbert L.
    Ghany, Marc G.
    Morishima, Chihiro
    HEPATOLOGY, 2009, 49 (06) : 1828 - 1837
  • [10] Dietary Cholesterol Intake Is Associated With Progression of Liver Disease in Patients With Chronic Hepatitis C: Analysis of the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial
    Yu, Lei
    Morishima, Chihiro
    Ioannou, George N.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2013, 11 (12) : 1661 - U208